The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 18, 2018
Filed:
Sep. 29, 2014
Applicants:
Duke University, Durham, NC (US);
Los Alamos National Security, Llc, Los Alamos, NM (US);
Inventors:
Barton F. Haynes, Durham, NC (US);
Bette T. Korber, Los Alamos, NM (US);
S. Munir Alam, Durham, NC (US);
Assignees:
DUKE UNIVERSITY, Durham, NC (US);
LOS ALAMOS NATIONAL SECURITY, LLC, Los Alamos, NM (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/21 (2006.01); A61K 38/16 (2006.01); A61K 38/21 (2006.01); A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 39/12 (2006.01); A61K 47/48 (2006.01); C07K 14/005 (2006.01); A61K 39/39 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 38/162 (2013.01); A61K 38/212 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 47/48815 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/575 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01);
Abstract
The present invention relates to peptides and compositions suitable for use in inducing anti-HIV-1 antibodies. The compositions comprise HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such compositions.